VIETER
VIETNAM MARKET INTELLIGENCE

Tissue Nanotransfection Market

Report Overview

The Global Tissue Nanotransfection Market size is expected to be worth around US$ 15.7 Billion by 2035 from US$ 3.4 Billion in 2025, growing at a CAGR of 16.5% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 42.2% share with a revenue of US$ 1.4 Billion.

Rising interest in regenerative medicine and non-viral gene delivery technologies propels the Tissue Nanotransfection market as researchers and clinicians seek precise, localized methods to reprogram cells directly within living tissue without systemic exposure or viral vectors. Scientists increasingly apply tissue nanotransfection to induce transdifferentiation in skin wounds, converting dermal fibroblasts into functional neurons or endothelial cells to accelerate nerve regeneration and vascularization in diabetic ulcers and spinal cord injuries.

Tissue Nanotransfection Market Size

  • In December 2025, Organogenesis began submitting a rolling Biologics License Application for ReNu, a biologic therapy under development for severe knee osteoarthritis. The product is intended to provide a non-surgical treatment option, with regulatory review expected to progress into 2026.